pain conditions
Groundbreaking immunotherapy to target endometriosis

A groundbreaking drug programme is set to target endometriosis using a novel Jun-N-terminal kinase (JNK) inhibitor that targets pain and inflammation.
The therapeutic drug candidate aims to address a critical unmet need in first-line treatments for a range of women’s health indications, starting with endometriosis and potentially extending to Polycystic Ovary Syndrome (PCOS) and ovarian ageing.
While traditionally viewed as the presence of endometrial-like tissue outside the uterus, it is increasingly recognised as a chronic inflammatory condition, potentially explaining its numerous associated health issues.
The current standard of care involves surgical removal of lesions or affected organs, though recurrence often necessitates repeated procedures. Symptom management typically relies on pain medications and hormonal therapies, which provide the impetus for developing related treatments.
Founder and CEO of Celmatix Therapeutics, which is developing the drug, Dr. Piraye Yurttas Beim, said: “Despite impacting one-in-ten women and girls, to date there have been no disease-altering, first-line medications brought to market to treat endometriosis.
“As someone who has been impacted by endometriosis since my first period, I can relate to the burden that this debilitating disease places on individuals, families, employers, and communities. Thanks to our decade-long multi-omics initiative, our research group was early in recognising that inflammation is core to the pathophysiology of endometriosis and may explain why it predisposes women for so many other health conditions down the road.
“Long after their periods have ended, women pay the price for their period pain having been papered over with painkillers and birth control pills rather than truly addressed and cured.
“I dream of a better health trajectory for my daughter and her peers and believe that our new JNK immunotherapy will unlock that brighter future.”
CSO of Celmatix Therapeutics,Dr. Stephen Palmer, said: “Endometriosis represents an opportunity to address both one of the most significant areas of unmet clinical need and one of the biggest commercial opportunities in women’s health.
“Our evaluation process to find the right drug programme to pursue involved a number of criteria, including target evaluation for anticipated safety, efficacy, and druggability. We also knew that we wanted to prioritise a biological target that was ideally involved in both the transmission of peripheral pain signals and inflammation.
“It rapidly became clear that a novel class of JNK inhibitors with greater specificity for JNK1 and 3 than for JNK 2 had the potential to meet our target product objectives. It was at that stage that we approached our colleagues at BCM to license lead compounds with many of the desired drug qualities.
“The promising JNK inhibitor scaffolds discovered at BCM have unique efficacy, potency, and safety signals achieved through novel interactions not previously addressed by other JNK inhibitors. The work on these compounds also confirmed reductions in inflammatory cytokines in models of endometriosis established for cell cultures and endometriosis lesion regression in rodent models.
“We are now rapidly progressing these licensed compounds through our internal lead optimisation efforts and are optimistic to be able to nominate a development candidate soon.”
“We are confident that Celmatix Therapeutics is the ideal partner for this innovative endometriosis treatment, with potential to expand into other women’s health indications,” said Dr. Martin Matzuk, director of the Center for Drug Discovery at BCM, who has dedicated over 30 years to discovering drug targets in women’s health.
“I have known members of the Celmatix team for over two decades, and they have a proven track record in research integrity and business acumen. The JNK project originated from screens using our sophisticated multi-billion compound DEC-Tec platform, and we are very pleased with the progress made by the Celmatix team.”
Diagnosis
Endometriosis study paves way for new diagnostics and treatments

A major genetics study has found dozens of new signals linked to endometriosis, offering fresh insight into the biology driving the condition.
Endometriosis is a systemic disease affecting around 10 per cent of females worldwide.
It happens when tissue similar to the lining of the uterus grows outside it, causing pain, inflammation and fertility problems.
Despite how common it is, the underlying causes have remained poorly understood, slowing progress in diagnosis and treatment.
In one of the largest investigations to date, researchers analysed genetic data from approximately 1.4 million females, including more than 105,000 with endometriosis.
The study identified 80 genomic regions linked to disease risk, including 37 previously unreported loci, or specific positions on chromosomes, significantly advancing understanding of endometriosis genetics.
Notably, five of these regions were also linked to adenomyosis, a related condition in which endometrial-like tissue grows within the wall of the uterus.
Beyond identifying genetic variants, the researchers integrated transcriptomic, epigenetic and proteomic data, which examine gene activity, chemical changes regulating genes and proteins, to better understand how these variants influence disease development.
This multi-omics approach linked endometriosis genetics to key biological processes, including cell differentiation, immune response, hormonal regulation, tissue remodelling and inflammation.
These findings support long-standing hypotheses that endometriosis is not solely a localised gynaecological condition but a complex, systemic disorder involving immune and hormonal dysregulation.
The study also found that genetic risk for endometriosis interacted with a range of clinical symptoms, including abdominal pain, anxiety, migraine and nausea.
This reinforces the multifaceted nature of the disease and may help explain why patients often experience a broad spectrum of symptoms beyond pelvic pain.
Such insights could improve patient stratification in the future, enabling more personalised approaches to management based on genetic risk profiles.
The analysis also identified potential therapeutic targets through drug-repurposing approaches.
Some of the implicated pathways overlap with those targeted by existing treatments for breast cancer, contraception and preterm birth prevention, raising the possibility of accelerating new treatment strategies for endometriosis.
Diagnosis
Women gaslit over hysteroscopy pain, Mumsnet posts reveal

Women have described being dismissed and left in serious pain during routine hysteroscopy examinations, with many given little or no pain relief.
Users of parenting forum Mumsnet who underwent hysteroscopy procedures also shared concerns about receiving unclear information before treatment and being given little or no pain relief afterwards.
Some women, who described feeling physically and emotionally vulnerable, compared the experience to sexual assault.
Research led by the University of Reading analysed 4,644 posts from Mumsnet users written between 2018 and 2024.
Susanne Cromme, lead author from the University of Reading, said: “Women in their thousands say they are going into hysteroscopy procedures unprepared, left in more pain than they were led to expect, and feeling that their experience is not being taken seriously, our analysis shows.
“This is not simply an online pile-on. The themes we found in our research are consistent with what clinical studies already tell us about hysteroscopy.
“But by listening to women talk to each other openly, without a researcher in the room, we get a much richer picture of the issues facing patients.”
The study was published following the launch of the Mumsnet campaign to End Medical Misogyny, which is fighting to end the “systemic dismissal, disbelief or de-prioritisation of women’s symptoms in healthcare”, and comes after health secretary Wes Streeting said the health system “too often gaslights women, treating their pain as an inconvenience.”
Justine Roberts, founder of Mumsnet and Gransnet, said: “This research makes clear that too many women are still experiencing severe pain during hysteroscopy, and that problem is compounded by unclear information, inconsistent pain relief and a lack of proper consent.
“These are not one-off failures, they form a repeated pattern and that’s exactly what Mumsnet’s medical misogyny campaign is highlighting: systemic failings in women’s healthcare.
“Nothing encapsulates that more clearly than the expectation that women should endure avoidable pain during gynaecological procedures. If the NHS is serious about tackling medical misogyny, this has to change.”
Around 71,000 hysteroscopy procedures take place every year in England.
According to the analysed Mumsnet posts, women were told procedures would be no worse than a smear test, felt unable to stop once they had started and found that the pain relief available depended entirely on which NHS trust they attended.
The analysis identified five recurring problems among hysteroscopy patients: not enough information before the procedure; women feeling exposed and unprotected; a “postcode lottery” for pain relief, with wide variation between trusts; pain being played down by staff; and an unequal standard of care.
Women also questioned why sedation routinely offered for procedures such as colonoscopies and endoscopies, which examine the bowel and digestive tract, was not available for gynaecological procedures.
The researchers said the findings suggest the problems go beyond individual clinicians, as the posts reflect wider structural issues in women’s healthcare, including potentially underfunded services and unequal standards of care.
The study calls for NHS trusts to introduce standardised consent processes that give women clear information about pain, alternatives and what to expect.
It also recommends consistent pain management protocols across all hospitals, and training for clinicians in trauma-informed care.
Diagnosis
New NHS pathways aims to speed up endometriosis diagnosis and treatment

A new NHS North West pathway aims to improve treatment and cut waits for people with endometriosis.
The pathway, launched in Cheshire and Merseyside, brings together primary care, secondary care and public health to reduce waiting times and recognise the condition earlier.
Endometriosis affects one in 10 women aged 15 to 45 and currently takes an average of eight years to diagnose.
The programme includes new learning resources for healthcare professionals and a renewed focus on raising public awareness of the condition.
Charlotte Martindale, 30, has had debilitating pain, heavy bleeding, nausea, bowel issues and fatigue for years, but her symptoms were attributed to anxiety and depression.
She said: “When I got to university the pain became unmanageable. I really felt as if I wasn’t being listened to and was made to feel like it was all in my head.”
Charlotte was incorrectly diagnosed with polycystic ovary syndrome (PCOS) before eventually being referred to gynaecology.
She says she was told a laparoscopy, the only definitive diagnostic procedure, would not be offered because she was not trying to conceive.
After 14 years of symptoms, an internal ultrasound finally revealed multiple endometriomas.
She was referred to the endometriosis centre in Preston and underwent surgery in 2025, where deep infiltrating endometriosis was found on her bladder, bowel and appendix, and had stuck her ovaries to her pelvic wall.
Although the surgery was successful, Charlotte has been told it is likely further surgery will be needed as the endometriosis regrows.
Data from the NHS Confederation showed that 84 per cent of women reported being dismissed by medical professionals.
Millie Campbell, 20, is still waiting for a formal diagnosis.
She has had heavy, erratic bleeding, pain and severe bloating since she was 12, but she was told she was “too young” to have endometriosis.
“I’ve been on several different contraceptive pills, but none of them have worked,” she said.
“The pain feels like a ball of barbed wire, and regular pain relief just doesn’t touch it.”
After an MRI last year, she is still waiting to find out whether she will be offered a laparoscopy.
Dr Paula Cowan, NHS England North West’s medical director for primary care and national specialty adviser with the women’s team, says the new approach marks an important step forward, but warns that significant challenges remain.
She said: “Early consideration and recognition of endometriosis is key, both in general practice and in the community. The earlier endometriosis is recognised and diagnosed, the better the care the NHS can give.”
“In this new pathway, we’ve looked closely at how engaging with patients and GPs, workforce planning and better use of data can help reduce waiting lists and ensure people get the help they need.”
“Too many women feel that they have not been listened to regarding their heavy, painful periods are normal.”
“From the very first contact with a patient presenting with heavy painful periods, we need to be thinking could this be endometriosis.”
Dr Cowan says the new pathway is part of a wider commitment to improving women’s health across the region.
Entrepreneur4 weeks agoFuture Fertility raises Series A financing to scale AI tools redefining fertility care worldwide
News3 weeks agoWomen’s digital health market set to reach US$5.28 billion in 2026 – report
Diagnosis4 weeks agoNew meta-analysis further supports low re-excisions and high placement accuracy with the Magseed marker
Diagnosis4 weeks agoNIPT or NT scan? Why the 2026 evidence supports doing Both
Menopause4 weeks agoResistance training has preventative effects in menopause, study finds
Mental health4 weeks agoLifting weights shows mental health and cognitive benefits in older women, study finds
Insight3 weeks agoWhy the UK’s fertility rate keeps falling – and what it means if you’re trying now
Wellness3 weeks agoWomen’s HealthX unveils Northwell Health, Corewell Health, Biogen & more to headline Chronic Disease stage












